1. Molecular Characterization and Structure
1.1 Chemical Structure and Genomic Encoding
Humanin is the founding member of the mitochondrial-derived peptide (MDP) family, discovered in 2001 by Hashimoto, Nishimoto, and colleagues [Hashimoto et al., 2001]. Encoded within the mitochondrial 16S ribosomal RNA gene (MT-RNR2), the transcript yields a 24-amino-acid peptide (MAPRGFSCLLLLTSEIDLPVKRRA) when translated on cytoplasmic ribosomes using the standard nuclear genetic code, or a 21-amino-acid C-terminally truncated peptide (ending at Val20-Lys21) when translated inside mitochondria where the AGA codon at position 22 functions as a mitochondrial stop codon. Additionally, nuclear mitochondrial DNA segments (NUMTs / nuclear pseudogenes such as MTRNR2L1–MTRNR2L12) reside across multiple human nuclear chromosomes.
| Parameter | Value | Notes |
|---|---|---|
| Amino Acid Sequence | MAPRGFSCLLLLTSEIDLPVKRRA | 24-mer peptide |
| Molecular Formula | C118H204N44O31S | Contains one cysteine residue |
| Molecular Weight | 2687.23 Da | Monoisotopic mass |
| CAS Registry Number | 330936-69-1 | Wild-type humanin (24-mer) |
| Isoelectric Point (pI) | 10.85 | Highly basic peptide |
| Net Charge at pH 7 | +4.1 | Cationic at physiological pH |
| Hydrophobicity (GRAVY) | 0.183 | Moderately hydrophobic |
| Genomic Origin | Mitochondrial 16S rRNA + nuclear pseudogenes | Dual genomic encoding |
| Extinction Coefficient | 6990 M-1cm-1 at 280 nm | Based on Phe content |
1.2 Structural Domains and Key Analogs (HNG & C8S)
Circular dichroism and solution NMR spectroscopy show that Humanin is largely unstructured in dilute aqueous buffer but adopts an amphipathic α-helical conformation spanning residues Gly5–Leu18 in membrane-mimetic environments. Systematic alanine-scanning mutagenesis identified Pro3, Phe6, Cys8, Leu9-Leu12, Thr13, and Ser14 as critical residues:
- HNG (S14G-Humanin): Substitution of L-Ser14 with achiral Gly14 (or D-Ser14) increases conformational flexibility at the C-terminal turn of the helix, enhancing neuroprotective and cytoprotective potency approximately 1,000-fold (effective in the sub-nanomolar range) [Hashimoto et al., 2001].
- C8S / C8A Substitution: While replacement of Cys8 with Arg (C8R) completely abolishes activity, replacement with Ser (C8S) retains cytoprotective activity while preventing oxidative intermolecular disulfide dimerization during storage.
2. Synthesis and Manufacturing
Humanin is synthesized via Fmoc solid-phase peptide synthesis (SPPS) on Wang or Rink amide resin. Due to the strongly hydrophobic tetra-leucine sequence (Leu9-Leu10-Leu11-Leu12), on-resin β-sheet aggregation can occur during chain assembly, requiring pseudoproline dipeptides, HATU/COMU coupling reagents, and aspartimide suppression at Asp17-Leu18.
| Quality Parameter | Specification | Analytical Method |
|---|---|---|
| Purity (HPLC) | ≥95.0% | RP-HPLC (220 nm) |
| Peptide Content | ≥90.0% | Amino acid analysis (AAA) |
| Sequence Verification | 100% match to MAPRGFSCLLLLTSEIDLPVKRRA | MS/MS sequencing |
| Molecular Weight | 2687.23 ± 2.0 Da | LC-MS or MALDI-TOF |
| Water Content | ≤10.0% | Karl Fischer titration |
| TFA Counter-Ion Content | ≤1.0% | Ion chromatography or 19F-NMR |
| Bacterial Endotoxins | ≤5 EU/mg | LAL assay |
| Monomer / Aggregation Profile | ≤3.0% aggregates by SEC | Size-exclusion chromatography |
3. Mechanism of Action
3.1 Intracellular Anti-Apoptotic Sequestration (Bax & IGFBP-3)
Inside the cytoplasm, Humanin directly binds the pro-apoptotic Bcl-2 family protein Bax (along with Bid and BimEL), stabilizing Bax in an inactive conformation and preventing its translocation to the outer mitochondrial membrane, oligomerization, and cytochrome c release [Guo et al., Nature 2003]. Independently, Humanin binds insulin-like growth factor-binding protein-3 (IGFBP-3) via its C-terminal domain, blocking IGFBP-3-induced nuclear apoptosis while preserving pro-survival IGF-1 receptor signaling.
3.2 Extracellular Trimeric Cytokine Receptor Complex (CNTFR / WSX-1 / gp130)
Secreted Humanin binds a heterotrimeric cell-surface receptor complex composed of Ciliary Neurotrophic Factor Receptor-α (CNTFRα), the IL-27 receptor subunit WSX-1 (IL-27Rα), and the signal-transducing subunit gp130 (and in innate leukocytes, formyl-peptide receptor-like-1, FPRL1/FPR2). Engagement of the CNTFR/WSX-1/gp130 complex activates Janus kinase 2 (JAK2) and phosphorylates STAT3 (Tyr705), alongside PI3K/Akt and ERK1/2 cascades, driving transcription of neuroprotective, cardioprotective, and hypothalamic insulin-sensitizing genes [Muzumdar et al., 2009].
4. Preclinical Research Evidence
| Disease / Condition | Model System | Key Preclinical Findings | Primary Citation |
|---|---|---|---|
| Alzheimer's Disease Neurotoxicity | Primary cortical neurons; APP/PS1 & 3xTg-AD mice | Abolished neuronal cell death induced by Aβ1-42 and familial AD mutants (APP V642I, PS1, PS2); improved spatial memory and reduced plaque burden | Hashimoto et al., 2001 |
| Cerebral Ischemia (Stroke) | MCAO rat model | Reduced infarct volume; improved neurological scores; decreased apoptosis | Xu et al., 2006 |
| Type 2 Diabetes & Central Insulin Action | Sprague-Dawley rats, db/db & HFD mice | Third-ventricle ICV or peripheral HNG infusion increased hepatic and muscle insulin sensitivity via hypothalamic STAT3 activation | Muzumdar et al., 2009 |
| Endothelial Oxidative Stress & Atherosclerosis | Human aortic endothelial cells; ApoE-/- mice | Expressed in vascular endothelium; suppressed oxLDL-induced ROS generation, ceramide accumulation, and atherosclerotic plaque progression | Bachar et al., 2010 |
| Retinal Pigment Epithelium (RPE) Degeneration | Primary human RPE cells under oxidative stress | Protected RPE mitochondria, increased PGC-1α and mtDNA copy number, and blocked stress-induced cellular senescence | Sreekumar et al., 2016 |
| Lifespan, Healthspan & Cognitive Aging | C. elegans, middle-aged mice, and human cohorts | daf-16/FOXO-dependent lifespan extension in C. elegans; attenuated age-related cognitive decline and systemic inflammation in aged mice | Yen et al., 2018; Yen et al., 2020 |
5. Human Observational and Clinical Studies
Human studies on Humanin focus primarily on translational biomarker correlations across aging, longevity, cardiovascular, and neurodegenerative cohorts:
| Study Design | Human Cohort | Key Biomarker / Clinical Findings | Reference |
|---|---|---|---|
| Cross-Sectional & Centenarian Offspring Cohorts | Aging adult cohorts & Ashkenazi Jewish centenarian offspring | Circulating plasma Humanin declines with age in humans and mice, whereas offspring of centenarians maintain ~2–3-fold higher circulating Humanin levels than age-matched controls | Muzumdar et al., 2009; Yen et al., 2020 |
| Coronary Endothelial Function Study | Patients undergoing coronary angiography for chest pain | Higher circulating endogenous Humanin levels correlated positively with preserved coronary endothelial blood flow response to acetylcholine and lower adverse cardiac event rates | Widmer et al., 2013 |
| Cognitive Aging & Alzheimer's Cohorts | Older human adults & AD cohorts | Plasma Humanin levels correlate with age-related physiological measures. | Yen et al., 2018 |
5.1 Genetic Variation and Humanin Levels
Research has identified genetic variants in mitochondrial DNA and nuclear Humanin-encoding pseudogenes that influence circulating Humanin levels and disease susceptibility. Certain mitochondrial haplogroups associate with higher Humanin production and reduced risk of age-related diseases, while polymorphisms in nuclear pseudogenes encoding Humanin also correlate with circulating peptide levels and metabolic phenotypes. These genetic findings support pharmacogenomic considerations that account for individual mitochondrial haplogroups and nuclear pseudogene genotypes when evaluating age-related disease risk or translational study stratification.
6. Analytical Methods and Quality Assessment
| Analytical Technique | Purpose | Key Parameters |
|---|---|---|
| RP-HPLC (C18, 214/220 nm) | Purity & oxidation/dimer resolution | ≥95.0% main peak; individual impurities <1.0% |
| ESI-MS or MALDI-TOF MS | Molecular weight confirmation | 2687.23 ± 2.0 Da |
| MS/MS Sequencing | Primary sequence confirmation | 100% sequence match; complete fragmentation coverage |
| Amino Acid Analysis (AAA) | Compositional verification & net content | All amino acids within ±10% of theoretical values |
| Circular Dichroism (CD) | Secondary structure assessment | Alpha-helical content in membrane-mimetic conditions |
| Size-Exclusion Chromatography (SEC) | Aggregation analysis | Monomer content ≥95%; aggregates <3% |
| Karl Fischer Titration | Water content | ≤10.0% |
| LAL Assay | Endotoxin testing | ≤5 EU/mg |
6.1 Biological Activity Assays
Functional bioassays verify that synthetic Humanin retains cytoprotective activity, including neuronal cell survival assays in primary cortical neurons or HT-22/SH-SY5Y cell lines challenged with beta-amyloid or serum deprivation (quantified by MTT or WST-1 viability), STAT3 phosphorylation assays, and CNTFR/WSX-1/gp130 trimeric receptor binding assays.
6.2 Quantification in Biological Samples
Measurement of endogenous Humanin in biological samples (plasma, serum, tissue extracts, cerebrospinal fluid) presents analytical challenges due to low physiological concentrations (typically picomolar to low nanomolar range) and complex biological matrices. Enzyme-linked immunosorbent assays (ELISA) represent the most common approach, employing antibodies specific for Humanin to achieve sensitive quantification with detection limits in the pg/mL range.
Mass spectrometry-based methods, particularly liquid chromatography-tandem mass spectrometry (LC-MS/MS), provide superior specificity and can simultaneously quantify multiple Humanin variants. These methods typically require sample enrichment steps such as solid-phase extraction or immunoaffinity purification to achieve adequate sensitivity, along with stable isotope-labeled internal standards to compensate for matrix effects and recovery variations. Standardization of Humanin measurement methods across laboratories remains an important priority for consistent biomarker research.
7. Research Applications and Experimental Uses
Humanin is widely deployed in mitochondrial biology and retrograde signaling studies alongside MOTS-c, in longevity and senescence research alongside Epithalon, and in cytoprotective and immunomodulatory studies alongside Thymosin Alpha-1 and BPC-157.
8. Preclinical Dosing Paradigms in Research Settings
Published rodent studies have used native Humanin doses ranging from 1–10 mg/kg body weight, whereas the more potent HNG (S14G) analog demonstrates efficacy at doses 100–1,000-fold lower, typically in the range of 1–100 μg/kg:
| Application | Humanin Dose | HNG Dose | Route | Frequency |
|---|---|---|---|---|
| Neuroprotection (acute) | 2–10 mg/kg | 10–100 μg/kg | IV, IP, ICV | Single or BID |
| Alzheimer's disease models | 1–5 mg/kg | 5–50 μg/kg | IP, SC | Daily for 4–12 weeks |
| Myocardial infarction | 5–10 mg/kg | 50–100 μg/kg | IV, IP | Before I/R or immediately after |
| Diabetes/metabolic models | 1–5 mg/kg | 10–50 μg/kg | IP, SC | Daily for 2–8 weeks |
| Stroke models | 5–10 mg/kg | 50–100 μg/kg | IV, IP | Post-MCAO, single or multiple doses |
| Aging/longevity studies | 0.5–2 mg/kg | 5–20 μg/kg | IP, SC, oral | Daily for months |
| Atherosclerosis models | 2–5 mg/kg | 20–50 μg/kg | IP, SC | 3x weekly for 8–16 weeks |
9. Storage and Handling Protocols
Because wild-type Humanin contains both Met1 (susceptible to sulfoxide formation) and a free thiol at Cys8 (susceptible to air-oxidation into an inactive disulfide dimer) as well as a hydrophobic Leu4 core prone to β-sheet aggregation at high ionic strength, lyophilized vials should be stored at -20°C to -80°C under inert gas and reconstituted gently in weakly acidic or low-ionic-strength sterile water before dilution into experimental buffers.
| Form | Storage Condition | Typical Stability | Handling Notes |
|---|---|---|---|
| Lyophilized powder (unopened) | -20°C to -80°C (freezer) | 12–24 months | Desiccated, oxygen-free environment |
| Lyophilized powder (unopened) | 2–8°C (refrigerator) | 3–6 months | Short-term storage only |
| Reconstituted aqueous solution | 2–8°C (refrigerator) | 5–7 days | Avoid high-salt PBS for concentrated stocks to prevent Leu4 aggregation |
| Single-use frozen aliquots | -80°C (ultra-low freezer) | 6–12 months | Thaw once only; avoid vortexing |
10. Safety Profile and Toxicology
In rodent acute and chronic toxicology studies (up to 14 months of twice-weekly IP administration in aging cohorts), Humanin and HNG exhibited wide tolerability margins with no organ histopathology or mortality. Because Humanin is a potent anti-apoptotic factor that blocks Bax activation, oncology models have investigated whether exogenous Humanin might protect tumor cells from chemotherapy; notably, studies in tumor-bearing mice showed that HNG protected normal host tissues from cyclophosphamide/bortezomib toxicity without promoting tumor growth or interfering with chemotherapeutic efficacy, though formal regulatory carcinogenicity studies remain uncompleted.
11. Literature Review and Research Trends
Following Hashimoto and Nishimoto's 2001 discovery of Humanin in AD-resistant occipital cortex [Hashimoto et al., 2001] and Guo and Reed's 2003 demonstration of direct Bax sequestration [Guo et al., 2003], work by Pinchas Cohen, Nir Barzilai, Kelvin Yen, and colleagues expanded Humanin biology to central insulin regulation [Muzumdar et al., 2009], endothelial protection [Bachar et al., 2010]; [Widmer et al., 2013], retinal mitochondrial protection [Sreekumar et al., 2016], cognitive aging [Yen et al., 2018], and centenarian longevity [Yen et al., 2020], catalyzing the discovery of MOTS-c [Lee et al., 2015].
12. References
- Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci U S A. 2001;98(11):6336-6341.
- Muzumdar RH, et al. Humanin: a novel central regulator of peripheral insulin action. PLoS One. 2009;4(7):e6334.
- Yen K, et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging. 2020;12(12):11185-11199.
- Bachar AR, et al. Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress. Cardiovasc Res. 2010;88(2):360-366.
- Xu X, et al. Humanin is a novel neuroprotective agent against stroke. Stroke. 2006;37(10):2613-2619.
- Guo B, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature. 2003;423(6938):456-461.
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454.
- Sreekumar PG, et al. The mitochondrial-derived peptide humanin protects RPE cells from oxidative stress, senescence, and mitochondrial dysfunction. Invest Ophthalmol Vis Sci. 2016;57(3):1238-1253.
- Widmer RJ, et al. The association of circulating humanin level with cardiovascular disease in elderly patients. J Clin Endocrinol Metab. 2013;98(8):E1360-E1363.
- Yen K, et al. Humanin prevents age-related cognitive decline in mice and is associated with improved cognitive age in humans. Sci Rep. 2018;8(1):14212.